May. 6 at 4:24 PM
$TDSGF potential ......
ADPT Adaptive Biotechnologies Q1 2026 revenue was
$70.9 million. The MRD business, which contributed 95% of revenue, grew 53% versus the first quarter of 2025. clonoSEQ® test volume in the first quarter of 2026 increased 41% to 32,595 tests delivered versus the first quarter of 2025.
$TDSGF and
$TELO.V MRD tests outperforms clonoSEQ.
Will the market ever recognize that fact and move up beyond .055 cents and .029 cents respectively?